Show simple item record

dc.contributor.author Szász, A Marcell
dc.contributor.author Lánczky A
dc.contributor.author Nagy, Ádám
dc.contributor.author Förster S
dc.contributor.author Hark K
dc.contributor.author Green JE
dc.contributor.author Boussioutas A
dc.contributor.author Busuttil R
dc.contributor.author Szabó, András
dc.contributor.author Győrffy, Balázs
dc.date.accessioned 2016-09-26T10:12:08Z
dc.date.available 2016-09-26T10:12:08Z
dc.date.issued 2016
dc.identifier 84981344780
dc.identifier.citation pagination=49322-49333; journalVolume=7; journalIssueNumber=31; journalTitle=ONCOTARGET;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/3674
dc.identifier.uri doi:10.18632/oncotarget.10337
dc.description.abstract INTRODUCTION: Multiple gene expression based prognostic biomarkers have been repeatedly identified in gastric carcinoma. However, without confirmation in an independent validation study, their clinical utility is limited. Our goal was to establish a robust database enabling the swift validation of previous and future gastric cancer survival biomarker candidates. RESULTS: The entire database incorporates 1,065 gastric carcinoma samples, gene expression data. Out of 29 established markers, higher expression of BECN1 (HR = 0.68, p = 1.5E-05), CASP3 (HR = 0.5, p = 6E-14), COX2 (HR = 0.72, p = 0.0013), CTGF (HR = 0.72, p = 0.00051), CTNNB1 (HR = 0.47, p = 4.3E-15), MET (HR = 0.63, p = 1.3E-05), and SIRT1 (HR = 0.64, p = 2.2E-07) correlated to longer OS. Higher expression of BIRC5 (HR = 1.45, p = 1E-04), CNTN1 (HR = 1.44, p = 3.5E- 05), EGFR (HR = 1.86, p = 8.5E-11), ERCC1 (HR = 1.36, p = 0.0012), HER2 (HR = 1.41, p = 0.00011), MMP2 (HR = 1.78, p = 2.6E-09), PFKB4 (HR = 1.56, p = 3.2E-07), SPHK1 (HR = 1.61, p = 3.1E-06), SP1 (HR = 1.45, p = 1.6E-05), TIMP1 (HR = 1.92, p = 2.2E- 10) and VEGF (HR = 1.53, p = 5.7E-06) were predictive for poor OS. MATERIALS AND METHODS: We integrated samples of three major cancer research centers (Berlin, Bethesda and Melbourne datasets) and publicly available datasets with available follow-up data to form a single integrated database. Subsequently, we performed a literature search for prognostic markers in gastric carcinomas (PubMed, 2012-2015) and re-validated their findings predicting first progression (FP) and overall survival (OS) using uni- and multivariate Cox proportional hazards regression analysis. CONCLUSIONS: The major advantage of our analysis is that we evaluated all genes in the same set of patients thereby making direct comparison of the markers feasible. The best performing genes include BIRC5, CASP3, CTNNB1, TIMP-1, MMP-2, SIRT, and VEGF.
dc.relation.ispartof urn:issn:1949-2553
dc.title Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients
dc.type Journal Article
dc.date.updated 2016-09-21T08:27:17Z
dc.language.rfc3066 en
dc.identifier.mtmt 3111905
dc.identifier.pubmed 27384994
dc.contributor.department SE/AOK/K/II. Sz. Gyermekgyógyászati Klinika
dc.contributor.institution Semmelweis Egyetem
dc.mtmt.swordnote FELTÖLTŐ: Sonnevend Kinga - sonnevend.kinga@med.semmelweis-univ.hu


Files in this item

xmlui.dri2xhtml.METS-1.0.onlyFromAllowedIP

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account